1. Home
  2. Press release
Jul 22, 2020 17:04 JST

Source: Eisai

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020

TOKYO, Jul 22, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020.

Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally. The latest data on the analysis of occurrence of amyloid-related imaging abnormalities-edema (ARIA-E) and brain Aβ levels from the ongoing open-label extension study (OLE) portion of the Phase II study (Study 201) will also be presented.

The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.

Eisai is also planning to host a satellite symposium "Development of the A/T/N/x Classification System for Different Context of Use Across the Alzheimer's Disease Continuum: State-of-the-Art and future Perspectives for Clinical Practice and Therapy Development". Dr. Jeffrey Cummings (Chair), Dr. Clifford Jack, and Dr. Kaj Blennow, three renowned AD researchers and clinicians, will provide a comprehensive overview of the significance and conceptual framework of the A/T/N/x categorization system in the AD continuum. Finally, they will hold a discussion on the future outlook of this classification system for Alzheimer's pharmacological trials and clinical practice.

Regarding aducanumab, for which submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval as an Alzheimer's Disease treatment was completed in July 2020, Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States) will conduct an oral presentation of the previously publicized topline results of Phase III studies EMERGE and ENGAGE. This data has been shared at prior medical congresses.

BAN2401 and aducanumab are being jointly developed by Eisai and Biogen Inc.

Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia. Eisai strives to create innovative medicines as soon as possible to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, those living with the disease and their families.

Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
 
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
 
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
 
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
 
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
 
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
 
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
 
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
More Press release >>

Latest Press Release


The 18th JCB World Conference Held in Incheon, Republic of Korea
Nov 07, 2025 18:00 JST

Olympus Unveils Corporate Strategy
Nov 07, 2025 15:30 JST

TANAKA's New Head Office, TANAKA Building Received The GOOD DESIGN AWARD 2025
Nov 07, 2025 04:00 JST

Honda Unveils Next-generation Technologies at "Honda Automotive Technology Workshop" for Electrified Models to be Launched in Second Half of 2020s
Nov 06, 2025 22:44 JST

Ten organizations have jointly launched a project titled "Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry"
Nov 06, 2025 22:00 JST

Fujitsu to develop new chatbot for Japan Pension Service
Nov 06, 2025 21:24 JST

Stripe and NEC to Provide Face Recognition Payment Service via Stripe Terminal
Nov 06, 2025 17:30 JST

ESA, MediaTek, Eutelsat, Airbus, Sharp, ITRI, and R&S Announce World's First Rel-19 5G-Advanced NR-NTN Connection over OneWeb LEO Satellites
Nov 06, 2025 17:00 JST

Hybrid Dump Truck Demonstration Test at South African Mining Site Selected by UNIDO's Industrial Cooperation Programme
Nov 06, 2025 16:16 JST

Mitsubishi Power Receives Contract to Upgrade Existing Boiler Equipment at the O Mon 1 Thermal Power Plant in Vietnam
Nov 06, 2025 16:01 JST

MHI and ICM Form Strategic Alliance to Advance Ethanol Dehydration Efficiency
Nov 06, 2025 15:38 JST

JCB and Agoda Enter Long-Term Partnership to Enhance Travel and Payment Experience Across Asia
Nov 06, 2025 12:00 JST

NEC and Siemens collaborate to accelerate smart factory innovation
Nov 05, 2025 00:57 JST

Exhibiting at the Space Tech Expo Europe 2025 in Bremen, Germany
Nov 05, 2025 00:49 JST

Honda Announces Electric Motorcycle Business Brand Promise and Four Core Values
Nov 05, 2025 00:35 JST

Honda Unveils Its First Electric Motorcycle, the Honda WN7, at EICMA 2025
Nov 05, 2025 00:20 JST

Honda Unveils V3R 900 E-Compressor Prototype Equipped with V3 Engine with Electronically-controlled Compressor at EICMA 2025
Nov 05, 2025 00:00 JST

Honda Presents World Premiere of CB1000GT Sport Tourer at EICMA 2025
Nov 04, 2025 23:55 JST

New CB1000GT, global debut of Honda WN7 electric motorcycle, expansion of Honda E-Clutch line-up and V3R 900 E-Compressor Prototype lead Honda's EICMA 2025 line-up
Nov 04, 2025 23:40 JST

Honda Motorcycle Business Product Marks and New Emblem
Nov 04, 2025 23:21 JST
 More Latest Release >>